The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 7904381.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (TH) cells. Vaccination of BALB/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ TH1 cells. These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need to induce cell-mediated immunity.
Medical subject headings
- Adjuvants, Immunologic
- Interleukins
- Leishmania major
- Leishmaniasis, Cutaneous
- Protozoan Vaccines
- T-Lymphocytes, Helper-Inducer